Stay updated with breaking news from Atxs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totalling 1,210,000 shares, a growth of 129.5% from the June 15th total of 527,300 shares. Based on an average daily trading volume, of 235,400 shares, the short-interest […] ....
683 Capital Management LLC purchased a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,718 shares of the biotechnology company’s stock, valued at approximately $219,000. Several other […] ....
Vivo Capital LLC boosted its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) by 68.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,681,199 shares of the biotechnology company’s stock after acquiring an additional 681,199 shares during the quarter. Astria Therapeutics comprises 2.9% of Vivo Capital LLC’s portfolio, making the […] ....
Opaleye Management Inc. grew its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) by 96.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 261,703 shares of the biotechnology company’s stock after acquiring an additional 128,203 shares during the period. Astria Therapeutics comprises 1.4% of Opaleye […] ....